title: Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid.
abstract: 5-Aminosalicylic acid, the therapeutically active metabolite of sulfasalazine, was exposed to oxygen-derived free radicals produced by the Fenton reaction in vitro, and several metabolites were detected and characterized by high performance liquid chromatography and ultraviolet spectrophotometry. The majority of these metabolites were present in methanolic extracts of feces samples from sulfasalazine-treated patients with inflammatory bowel disease but not in rheumatoid arthritis patients with normal bowel function. The presence of these metabolites, which have not been demonstrated in vivo before, provides evidence of an interaction between 5-aminosalicylic acid and oxygen-derived free radicals in sulfasalazine-treated patients with inflammatory bowel disease. Since the concentration of lipid peroxides, which is dependent on the release of oxygen-derived free radicals, was significantly increased in pretreatment rectal biopsies of the patients, and further was normalized concomitantly with a significant improvement in disease activity over the 5-wk treatment period, an important role of the radical scavenger mechanism of 5-aminosalicylic acid in sulfasalazine therapy of chronic inflammatory bowel disease is strongly suggested.
authors.affiliation: Department of Pharmacology, Leo Pharmaceutical Products, Ballerup, Denmark.
authors.forename: I
authors.initials: I
authors.lastname: Ahnfelt-Rønne
authors.forename: O H
authors.initials: OH
authors.lastname: Nielsen
authors.forename: A
authors.initials: A
authors.lastname: Christensen
authors.forename: E
authors.initials: E
authors.lastname: Langholz
authors.forename: V
authors.initials: V
authors.lastname: Binder
authors.forename: P
authors.initials: P
authors.lastname: Riis
mesh_terms: D000328:Adult; D000368:Aged; D000636:Aminosalicylic Acids / Q000032:analysis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001706:Biopsy; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000378:metabolism; D003109:Colonic Diseases, Functional / Q000188:drug therapy / Q000378:metabolism; D003424:Crohn Disease / Q000188:drug therapy / Q000378:metabolism; D005243:Feces / Q000032:analysis; D005260:Female; D005609:Free Radicals; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D019804:Mesalamine; D008875:Middle Aged; D010084:Oxidation-Reduction / Q000187:drug effects; D012007:Rectum / Q000378:metabolism / Q000473:pathology; D012460:Sulfasalazine / Q000032:analysis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000636:Aminosalicylic Acids; D005609:Free Radicals; D012460:Sulfasalazine; D019804:Mesalamine